


PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions
and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A pyrazole derivative represented by the
following general formula (I α) :




wherein

R¹ represents a hydrogen atom, a C₁₋₆ alkyl group which
may have the same or different 1 to 3 groups selected from the
following substituent group (A), a C₂₋₆ alkenyl group which may
have the same or different 1 to 3 groups selected from the
following substituent group (A), a C₂₋₆ alkynyl group which may
have the same or different 1 to 3 groups selected from the
following substituent group (A), a C₃₋₈ cycloalkyl group which
may have the same or different 1 to 3 groups selected from the
following substituent group (A), a C₆₋₁₀ aryl group which may
have the same or different 1 to 3 groups selected from the
following substituent group (B), a C₂₋₉ heterocycloalkyl group

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q⁰ and T⁰ represents a group selected from



and the other represents a group represented by the formula: - (CH₂)_n-Ar wherein Ar represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a C₁₋₆ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A), an optionally mono or di(C₁₋₆ alkyl)-substituted amino group wherein the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

from the following substituent group (A), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G¹, -OG², -SG², -N(G²)₂, -C(=O)G², -C(=O)OG², -C(=O)N(G²)₂, -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹, -OC(=O)G¹, -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹ and -C(=O)NHS(=O)₂G¹;

[substituent group (B)]:

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

G^2 represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G^2 may be the same or different when there are 2 or more G^2 in the substituents;

G^3 represents a C₁₋₆ alkyl group;

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^4 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G^4 may be the same or different when there are 2 or more G^4 in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C) and/or (D),

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and


G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^6 may be the same or different when there are 2 or more G^6 in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (original): A pyrazole derivative as claimed in claim 1, wherein

R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); Q^0 represents a C_{6-10} aryl group which may have the

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

same or different 1 to 3 groups selected from the substituent group (B); T^0 represents a group:




; R represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); substituent group (A) consists of a halogen atom, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2OG^2$ and $-S(=O)_2N(G^2)_2$ in which G^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C); or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-C(=O)OG^2$ in which G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and G^2 has the same meaning as defined

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)


above, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

3. (original): A pyrazole derivative as claimed in claim 1, wherein one of Q^0 and T^0 represents a group selected from



and the other represents a group represented by the formula: -
 $(CH_2)_n-Ar$, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

4. (original): A pyrazole derivative as claimed in claim 3, wherein Q^0 represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); T^0 represents a group selected from




and R represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

5. (original): A pyrazole derivative as claimed in claim 4,
wherein


T^0 represents a group:



; and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$ and $-C(=O)OG^2$ in which G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and G^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

6. (original): A pyrazole derivative as claimed in claim 1,
wherein one of Q^0 and T^0 represents a group selected from


PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)



and the other represents a C₁-6 alkoxy group which may have the same or different 1 to 3 groups selected from the substituent group (A), an optionally mono or di(C₁-6 alkyl)-substituted amino group in which the C₁-6 alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a C₂-9 heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a pharmaceutically acceptable salt thereof or a prodrug thereof.


7. (original): A pyrazole derivative as claimed in claim 6, wherein Q⁰ represents an optionally mono or di(C₁-6 alkyl)-substituted amino group in which the C₁-6 alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a C₂-9 heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A); and T⁰ represents a group selected from

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)



or a pharmaceutically acceptable salt thereof or a prodrug thereof.


8. (original): A pyrazole derivative as claimed in claim 1,
wherein one of Q^0 and T^0 represents a group selected from



and the other represents a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

9. (original): A pyrazole derivative as claimed in claim 8, wherein Q^0 represents a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the substituent group (B); and T^0 represents a group selected from


PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)



or a pharmaceutically acceptable salt thereof or a prodrug thereof.

10. (currently amended): A pharmaceutical composition comprising as an active ingredient a pyrazole derivative as claimed in ~~any one of claims 1-9~~ claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

11. (original): An inhibitor of 1,5-anhydroglucitol/fructose/mannose transporter comprising as an active ingredient a pyrazole derivative represented by the following general formula (I):




wherein

R^1 represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkynyl group which may

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

have the same or different 1 to 3 groups selected from the following substituent group (A), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from



and the other represents a group represented by the formula: -
(CH₂)_n-Ar wherein Ar represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a C₁₋₆ alkyl group which may have

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

the same or different 1 to 3 groups selected from the following substituent group (A), a C₁₋₆ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A), an optionally mono or di(C₁₋₆ alkyl)-substituted amino group wherein the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

which may have the same or different 1 to 3 groups selected from the following substituent group (B) ;

[substituent group (A)] :

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

[substituent group (B)] :

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B) ,

G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C) , a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C) , a C_{2-6} alkynyl group which may have the

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

G² represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G² may be the same or different when there are 2 or more G² in the substituents;

G³ represents a C₁₋₆ alkyl group;

G⁴ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G⁴ may be the same or different when there are 2 or more G⁴ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and

[substituent group (D)]:

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C) and/or (D),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^6 may be the same or different when there are 2 or more G^6 in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

12. (currently amended): An inhibitor of 1,5-anhydroglucitol/fructose/mannose transporter comprising as an active ingredient a pyrazole derivative as claimed in ~~any one of claims 1-9~~ claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

13. (original): An agent as claimed in claim 11, which is an agent for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose.

14. (currently amended): An agent for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose comprising as an active ingredient a pyrazole derivative as claimed in ~~any one of claims 1-9~~claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

15. (original): An agent as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetic complications.

16. (original): An agent as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetic complications.

17. (original): An agent as claimed in claim 15, wherein the diabetic complications is diabetic nephropathy.

18. (original): An agent as claimed in claim 16, wherein the diabetic complications is diabetic nephropathy.

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

19. (original) : An agent as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetes.

20. (original) : An agent as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetes.

21. (currently amended) : A pharmaceutical combination which comprises (component a) a pyrazole derivative as claimed in ~~any one of claims 1-9~~claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof, and (component b) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a


PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhidantoin, EGB-761, bimoclomol, sulodexide, Y-128, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibrin acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

22. (original): A pyrazole derivative represented by the following general formula (II α):




wherein

R^{1A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₃₋₈ cycloalkyl group which

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^{A0} and T^{A0} represents a group selected from



ing protective group(s), and the other represents a group represented by the formula: -(CH₂)_n-Ar^A wherein Ar^A represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n represents an integral number from 0 to 2, a C₁₋₆ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), an

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

optionally mono or di(C₁₋₆ alkyl)-substituted amino group
wherein the C₁₋₆ alkyl group may have the same or different 1
to 3 groups selected from the following substituent group
(A1), a C₂₋₉ heterocycloalkyl group which may have the same or
different 1 to 3 groups selected from the following
substituent group (A1), or a heterocycle-fused phenyl group
which may have the same or different 1 to 3 groups selected
from the following substituent group (B1);

R^A represents a C₃₋₈ cycloalkyl group which may have the
same or different 1 to 3 groups selected from the following
substituent group (A1), a C₆₋₁₀ aryl group which may have the
same or different 1 to 3 groups selected from the following
substituent group (B1), a C₂₋₉ heterocycloalkyl group which may
have the same or different 1 to 3 groups selected from the
following substituent group (A1), or a C₁₋₉ heteroaryl group
which may have the same or different 1 to 3 groups selected
from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo
group, -G^{1A}, -OG^{2B}, -SG^{2B}, -N(G^{2B})₂, -C(=O)G^{2A}, -C(=O)OG^{2B}, -
C(=O)N(G^{2B})₂, -S(=O)₂G^{2A}, -S(=O)₂OG^{2A}, -S(=O)₂N(G^{2B})₂, -

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

$S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$,
 $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)] :

a halogen atom, a nitro group, a cyano group, $-G^{1A}$,
 $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$,
 $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$,
 $S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$,
 $NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

G^{1A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^{2B} represents a protective group, a hydrogen atom, a C_1 - 6 alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G^3 represents a C_{1-6} alkyl group;

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C1) and/or (D1),


G^5 represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group;

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^6 represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.

23. (original): A pyrazole derivative represented by the following general formula (III α):



wherein

R^{1A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkenyl group which

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^{B0} and T^{B0} represents a hydroxy group, and the other represents a group represented by the formula: -(CH₂)_n-Ar^A wherein Ar^A represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n represents an integral number from 0 to 2, a C₁₋₆ alkoxy group which may have the same

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

or different 1 to 3 groups selected from the following substituent group (A1), an optionally mono or di(C₁₋₆ alkyl)-substituted amino group wherein the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G^{1A}, -OG^{2B}, -SG^{2B}, -N(G^{2B})₂, -C(=O)G^{2A}, -C(=O)OG^{2B}, -

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

$C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

G^{1A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^{2B} represents a protective group, a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G^3 represents a C_{1-6} alkyl group;

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^{4A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C1) and/or (D1),

PRELIMINARY AMENDMENT
(371 of PCT/JP2003/012477)

G^5 represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group;

G^6 represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.